Immunotherapy in Combination with Chemotherapy for Triple-negative Breast Cancer.

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks estrogen and progesterone receptors and does not overexpress the human epidermal growth factor receptor 2 (HER2). Previous treatment options for TNBC were limited to chemotherapy alone, resulting in a poor patient prognosis. In 2018, an estimated 2.